DE602004019135D1 - Screeningverfahren für Kombinationen von biologischen Verbindungen - Google Patents

Screeningverfahren für Kombinationen von biologischen Verbindungen

Info

Publication number
DE602004019135D1
DE602004019135D1 DE602004019135T DE602004019135T DE602004019135D1 DE 602004019135 D1 DE602004019135 D1 DE 602004019135D1 DE 602004019135 T DE602004019135 T DE 602004019135T DE 602004019135 T DE602004019135 T DE 602004019135T DE 602004019135 D1 DE602004019135 D1 DE 602004019135D1
Authority
DE
Germany
Prior art keywords
compounds
cancer
combinations
screening method
biological compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004019135T
Other languages
English (en)
Inventor
Mark Nesbit
Alfred P Spada
Wei He
Michael R Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centelion SAS
Aventis Pharmaceuticals Inc
Original Assignee
Centelion SAS
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion SAS, Aventis Pharmaceuticals Inc filed Critical Centelion SAS
Publication of DE602004019135D1 publication Critical patent/DE602004019135D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602004019135T 2003-10-07 2004-10-07 Screeningverfahren für Kombinationen von biologischen Verbindungen Active DE602004019135D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50885903P 2003-10-07 2003-10-07
PCT/EP2004/012185 WO2005038465A2 (en) 2003-10-07 2004-10-07 Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
DE602004019135D1 true DE602004019135D1 (de) 2009-03-05

Family

ID=34465087

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004019135T Active DE602004019135D1 (de) 2003-10-07 2004-10-07 Screeningverfahren für Kombinationen von biologischen Verbindungen

Country Status (6)

Country Link
EP (1) EP1687642B1 (de)
AT (1) ATE421094T1 (de)
CA (1) CA2549579A1 (de)
DE (1) DE602004019135D1 (de)
DK (1) DK1687642T3 (de)
WO (1) WO2005038465A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128740A2 (en) * 2005-06-02 2006-12-07 Centelion Anti-vascular methods and therapies employing lysyl oxidase inhibitors
US8900619B2 (en) * 2006-08-24 2014-12-02 Boston Scientific Scimed, Inc. Medical devices for the release of therapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926888T2 (de) * 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
ES2108120T3 (es) * 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US6180632B1 (en) * 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
EP1490362A2 (de) * 2001-03-08 2004-12-29 Millennium Pharmaceuticals, Inc. (homo)piperazin substituierte chinoline zur hemmung der phosphorylierung von kinasen

Also Published As

Publication number Publication date
WO2005038465A3 (en) 2005-09-15
ATE421094T1 (de) 2009-01-15
EP1687642A2 (de) 2006-08-09
WO2005038465A2 (en) 2005-04-28
CA2549579A1 (en) 2005-04-28
DK1687642T3 (da) 2009-05-11
EP1687642B1 (de) 2009-01-14

Similar Documents

Publication Publication Date Title
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
DE60329990D1 (de) Mitotische kinesin-hemmer
MY148985A (en) 2-aminopyridine analogs as glucokinase activators
DE60329756D1 (de) Mitotische kinesin-hemmer
DE60312516D1 (de) Inhibitoren von mitotischem kinesin
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
RS48804A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
TW200740808A (en) Inhibiteurs de proteines kinases
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
ATE482218T1 (de) Inhibitoren von mitotischem kinesin
DE602004019135D1 (de) Screeningverfahren für Kombinationen von biologischen Verbindungen
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition